Location · Media, PA
Clinical trials in Media, PA
10 recruiting studies have a site in Media, and 0 of them accept healthy volunteers.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Takeda
- Location
- Media, PA + 42 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Sanofi
- Location
- Media, PA + 70 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Media, PA + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
Draig Therapeutics Ltd
- Location
- Media, PA + 19 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Media, PA + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
Mirum Pharmaceuticals, Inc.
- Location
- Media, PA + 13 other US sites
- Eligibility basics
- Ages 13–45 · Men only
- RecruitingPhase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Media, PA + 24 other US sites
- Eligibility basics
- Any age listed
- RecruitingPhase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.
- Location
- Media, PA + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Media, PA + 35 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 2
Study of ALTO-300 in MDD
Alto Neuroscience
- Location
- Media, PA + 36 other US sites
- Eligibility basics
- Ages 18–70